Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
Stocks in this Quantisnow insightHealth Care
Historical context for CRDL
Across the 21 sessions after earlier CRDL headlines, the stock closed higher 13 times and lower 7 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CRDL | SPY |
|---|---|---|---|
| Sep 9, 2026 | Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference | +2.9% | -0.5% |
| Aug 26, 2026 | B. Riley Securities initiated coverage on Cardiol Therapeutics with a new price target | +7.0% | +0.0% |
| Aug 5, 2026 | Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference | -1.5% | -0.2% |
| Jul 14, 2026 | Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association | +8.5% | +0.4% |
| Jul 9, 2026 | Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit | -0.8% | +0.8% |
| Jun 25, 2026 | Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | +1.0% | +0.1% |
Quantisnow market dataNASDAQ
CRDL
Cardiol Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for CRDL
Full CRDL profile on Quantisnow Follow CRDL and get a push notification the moment its next story breaks.